NASDAQ:EYPT Eyepoint Pharmaceuticals Q3 2026 Earnings Date & Estimates $3.46 +0.14 (+4.22%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$3.46 0.00 (-0.14%) As of 07:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Eyepoint Pharmaceuticals is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Eyepoint Pharmaceuticals in Q3 2026Eyepoint Pharmaceuticals is expected to post earnings of -$0.91 per share on revenue of $0.23 million. In the same quarter a year earlier Eyepoint Pharmaceuticals reported -$0.85 per share on revenue of $0.97 million. Eyepoint Pharmaceuticals last reported on August 5, 2026, posting -$1.09 per share and missing the -$1.01 consensus estimate. Eyepoint Pharmaceuticals has beaten the consensus EPS estimate in 0 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.91Expected Revenue$0.23 millionPrior-Year EPS-$0.85Prior-Year Revenue$0.97 millionExpected Revenue Growth-76.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.09 (Missed by -$0.08)Last Quarter Revenue$0.51 millionEPS Beat Rate0 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Eyepoint Pharmaceuticals Q3 2026 Earnings FAQ When does Eyepoint Pharmaceuticals report Q3 2026 earnings? Eyepoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. What time is Eyepoint Pharmaceuticals' Q3 2026 earnings call? Eyepoint Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Eyepoint Pharmaceuticals? Analysts expect Eyepoint Pharmaceuticals to post earnings of -$0.91 per share for Q3 2026. How much revenue is Eyepoint Pharmaceuticals expected to report? The consensus revenue estimate for Eyepoint Pharmaceuticals is $0.23 million for Q3 2026. Eyepoint Pharmaceuticals Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTOctober 6 at 5:36 PM | globenewswire.comHead-To-Head Analysis: Eyepoint Pharmaceuticals (NASDAQ:EYPT) versus GSK (NYSE:GSK)October 4, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 9 at 1:00 AM | Stansberry Research (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTOctober 1, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 29, 2026 | globenewswire.comJonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)September 29, 2026 | theglobeandmail.comSee More Eyepoint Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eyepoint Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyepoint Pharmaceuticals and other key companies, straight to your email. Email Address About Eyepoint PharmaceuticalsEyepoint Pharmaceuticals (NASDAQ:EYPT) is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions. EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery. The company also maintains a development pipeline centered on retinal diseases and other ophthalmic conditions. The company was formerly known as pSivida Corp. and adopted the EyePoint Pharmaceuticals name in 2018. Based in Watertown, Massachusetts, EyePoint develops and markets its therapies primarily for the U.S. ophthalmology market while pursuing additional development and commercial opportunities through collaborations and international regulatory activities.View Eyepoint Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
